

# CURRICULUM VITAE



**Hans-Peter Kohler, MD**

**Professor of Internal Medicine**

**University Hospital of Bern, Switzerland**

**Research:**

**Head, FXIII Research Group,  
Department of Clinical Research,  
Laboratory for Thrombosis Research,  
Kinderklinik G3, Room 835**

Inselhospital, 3010 Bern, Switzerland

Tel: +41 31 632 19 87

Fax: +41 31 974 24 61

e-mail: [hanspeter.kohler@insel.ch](mailto:hanspeter.kohler@insel.ch)

# CV - Kohler Hans-Peter MD

## Personal data :

Name : Kohler Hans-Peter  
Date of birth : 19.02.1960

**Present functions :** **Professor of Internal Medicine,**  
Inselspital, University Hospital of Berne, Switzerland

**Head FXIII-Thrombosis Research Group,** Department of Clinical Research,  
University of Bern, Switzerland

## Medical Education :

1984 - 91 Faculty of Medicine, University of Berne, Switzerland  
1991 Graduation from Medical School and MD graduation  
2001 Nomination as Reader in Internal Medicine  
2005 Nomination as Professor of Internal Medicine

## Professional occupations , Post-Graduate Training:

91 – 01.92 House Officer, Clinic of Internal Medicine, District Hospital of Herzogenbuchsee, Switzerland

02.92 – 06.93 Research Fellowship, Laboratory for Thrombosis Research, Department of Internal Medicine, University Hospital of Berne  
Research project on whole blood coagulation (Protein C activation and thrombin generation in non-anticoagulated whole blood in contact with human umbilical cord endothelial cells, HUVEC`s))  
(Prof. PW Straub, Prof A. Haeberli)

07.93 – 06.95 Senior House Officer, Clinic of Internal Medicine, Teaching Hospital of Langenthal, Switzerland  
(Prof. R.A. Streuli)

07.95 – 06.96 Registrar, Department of Internal Medicine, University Hospital of Berne

09.96 – 09.98 Research Fellowship at the **University of Leeds, England,**  
Unit of Molecular Vascular Medicine  
(Project: „Functional analysis of the factor XIII gene and its relationship to cardio- and cerebrovascular diseases.“)  
In addition, study of several other genetic polymorphisms and cardiovascular risk.  
The following genes has been further studied: PAI-1, fibrinogen, FXII and FV Leiden.

(Prof. P.J. Grant)

- 09.98-03.99            Consultant, Department of Internal Medicine, University Hospital of Berne  
Continuation of the research projects in collaboration with the University of Leeds  
(Research School of Medicine, Unit of Molecular Vascular Medicine)  
(Prof. PW Straub, Prof. F.Frey)
- since May 1999        Consultant in Internal Medicine at the Department of Trauma and Emergency  
Medicine, University Hospital of Berne
- 01.06.99                Nomination as Head of the Clinical Investigation Unit (CIU), University of Berne
- 01.08.99                Nomination as Head of Internal Medicine,  
Department of Trauma and Emergency Medicine , University Hospital of Berne  
Switzerland
- Since 1.2000            Head FXIII-Thrombosis Research Group, Department of Clinical Research,  
University of Bern, Switzerland
- Since 4.2001            Reader in Internal Medicine (PD Dr. med.)
- Since 2005:             Professor of Internal Medicine  
University Hospital of Bern, Switzerland
- Head FXIII-Research Group, Department of Clinical Research,  
University Hospital of Bern, Switzerland

### **Work within the “International Society on Thrombosis and Haemostasis”**

Active Member of the ISTH FXIII Scientific Subcommittee (Members: Charles Greenberg, USA; Laszlo Muszbek, Hungary; Hans Peter Kohler, Switzerland).

Co-Chairman of the SSC Scientific Subcommittee together with A. Ichinose, Japan;  
P. Bishop, USA; Prof. R. Seitz, Germany; R Ariens (Chair), England.

### **Regular Reviewer for the following journals:**

- Thrombosis and Haemostasis
- Arteriosclerosis Thrombosis and Vascular Biology
- Blood
- Lancet
- Blood Coagulation & Fibrinolysis
- Swiss Medical Weekly
- GUT
- Clinical Chemistry
- Biochemica Biophysica Acta
- European Journal of Endocrinology
- American Journal of Clinical Nutrition
- Journal of Women`s Health

-BioEssays  
 -Haematologica  
 -European Heart Journal

### Articles in peer-reviewed Journals (indexed in MEDLINE) JCR 2003

		Ranking	IF Impact factor
1	Biedermann B, Rosenmund A, Müller M, <u>Kohler HP</u> , Haeberli A, Straub PW. Human endothelial cells suppress prothrombin activation in non-anticoagulated whole blood in vitro. <i>J Lab Clin Med</i> 124:339-347,1994.	6/24	2.0
2	<u>Kohler HP</u> , Müller M, Bombeli T, Straub PW, Haeberli A. The suppression of the coagulation of non-anticoagulated whole blood in vitro by human umbilical endothelial cells cultivated on microcarriers is not dependent on protein C activation. <i>Thromb Haemost</i> 73:719-24,1995.	8/61	4.9
3	<u>Kohler HP</u> , Boothby M, McCormack LJ, Knowler WC, Grant PJ. Incidence of Arg506/Gln mutation (Factor V Leiden) in Pima Indians. <i>Thromb Haemost</i> 78:961-962,1997.	8/61	4.9
4	<u>Kohler HP</u> , Stickland MH, Ossei-Gerning N, Carter AM, Mikkola H, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. <i>Thromb Haemost</i> 79: 8-13,1998.	8/61	4.9
5	<u>Kohler HP</u> , Braunschweig M, Triller J, Cerny A. Sudden abdominal pain and jaundice in a young man. <i>Hospital Practice</i> 33:139-143, 1998.		
6	<u>Kohler HP</u> , Carter AM, Stickland MH, Grant PJ. Levels of activated factor XII in survivors of myocardial infarction. Association with circulating risk factors and extent of coronary artery disease. <i>Thromb Haemost</i> 79: 14-18,1998.	8/61	4.9
7	<u>Kohler HP</u> , Ariëns RAS, Whitaker P, Grant PJ. A common coding polymorphism in the factor XIII A-subunit gene (FXIIIVal34Leu) affects cross-linking activity. <i>Thromb Haemost</i> 80:704, 1998.	8/61	4.9
8	<u>Kohler HP</u> , Grant PJ. Clustering of FXIIIVal34Leu with haemostatic risk factors in patients with myocardial infarction. <i>Thromb Haemost</i> 80:862, 1998.	8/61	4.9
9	Catto AJ, <u>Kohler HP</u> , Bannen S, Stickland MH, Carter AM, Grant PJ. Factor XIII gene Val34Leu polymorphism: a novel association with primary intracerebral haemorrhage. <i>Stroke</i> 29: 813-816,1998.	6/52	5.2
10	McCormack LJ, Kain K, Catto AJ, <u>Kohler HP</u> , Stickland MH, Grant PJ. Prevalence of FXIIIVal34Leu in populations with different cardiovascular risk. <i>Thromb Haemost</i> 80:523-524,1998.	8/61	4.9
11	<u>Kohler HP</u> , Grant PJ. Role of Factor XIIIVal34Leu in cardiovascular disease . <i>Q J Med</i> 92:67-72, 1999.	17/102	2.4
12	<u>Kohler HP</u> , Futers TS, Grant PJ. FXII (46 C/T) polymorphism and in vivo generation of FXII activity. <i>Thromb Haemost</i> 81:745-747, 1999.	8/61	4.9
13	<u>Kohler HP</u> , Futers TS, Grant PJ. Prevalence of three common polymorphisms in the A-subunit gene of FXIII in patients with coronary artery disease. Association with FXIII activity and antigen levels. <i>Thromb Haemost</i> 81:511-515, 1999.	8/61	4.9
14	<u>Kohler HP</u> , Mansfield MW, Clark PS, Grant PJ. Interaction between insulin resistance and factor XIIIVal34Leu in patients with coronary artery disease.	8/61	4.9

*Thromb Haemost* 82:1202-1203, 1999.

- |    |   |        |      |
|----|---|--------|------|
| 15 | Ariëns RAS, <u>Kohler HP</u> , Mansfield MW, Grant PJ. Activity and subunit antigen levels of blood coagulation factor XIII: relationship to age, smoking and hypertension in healthy individuals.<br><i>Arterioscler Thromb Vasc Biol</i> 19:2012-2016, 1999.  | 4/61   | 6.8  |
| 16 | Catto AJ, <u>Kohler HP</u> , Coore J, Mansfield MW, Stickland MH, Grant PJ. Association of a common polymorphism in the factor XIII gene with venous thrombosis.<br><i>Blood</i> 93:906-908,1999.   | 2/61   | 10.1 |
| 17 | Mansfield MW, <u>Kohler HP</u> , Ariëns RAS, Grant PJ. Circulating levels of coagulation factor XIII in subjects with type II diabetes mellitus and their first-degree relatives.<br><i>Diabetes Care</i> 23:703-705, 2000 .  | 7/88   | 7.5  |
| 18 | Carter AM, Catto AJ, <u>Kohler HP</u> , Ariëns RAS, Stickland MH, Grant PJ. alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism.<br><i>Blood</i> 93:1177-1179, 2000.   | 2/61   | 10.1 |
| 19 | Schroeder V, <u>Kohler HP</u> . Effect of factor XIIIVal34Leu on $\alpha_2$ -antiplasmin incorporation into fibrin.<br><i>Thromb Haemost</i> 84:1128-30, 2000.  | 8/61   | 4.9  |
| 20 | <u>Kohler HP</u> , Grant PJ. Plasminogen activator inhibitor-1 and coronary artery disease. (Mechanisms of Disease).<br><i>N Engl J Med</i> 342:1792-1801, 2000.  | 1/102  | 34.8 |
| 21 | <u>Kohler HP</u> , Ariëns RAS, Mansfield MW, Whitaker P, Grant PJ. Factor XIII activity and antigen levels in patients with coronary artery disease.<br><i>Thromb Haemost</i> 85:569-70, 2001.  | 8/61   | 4.9  |
| 22 | Wilmer M, Rudin K, Kolde HJ, Poetzsch B, Lenz W, Moessmer G, Meili E, Egbring R, Gempeler P, Gempeler M, Bastian S, <u>Kohler HP</u> . Evaluation of a sensitive colorimetric FXIII incorporation assay. Effects of FXIIIVal34Leu, plasma fibrinogen concentration and congenital FXIII deficiency.<br><i>Thromb Res</i> 102:81-91, 2001. | 29/61  | 1.8  |
| 23 | Schroeder V, <u>Kohler HP</u> . Influence of blood coagulation factor XIII and FXIIIVal34Leu on plasma clot formation measured by thromboelastography.<br><i>Thromb Res</i> 104:467-474, 2001.  | 29/61  | 1.8  |
| 24 | <u>Kohler HP</u> . Role of blood coagulation factor XIII in vascular diseases.<br><i>Swiss Medical Weekly</i> 131:31-34, 2001.  | 37/102 | 1.5  |
| 25 | <u>Kohler HP</u> , Ariëns, RAS, Catto AJ, Carter AM, Miller GJ, Cooper JA, Mansfield MW, Standeven KF, Grant PJ. Factor XIII A subunit concentration predicts outcome in stroke subjects and vascular outcome in healthy middle aged males.<br><i>Brit J Haematol</i> 118:825-832, 2002.  | 14/61  | 3.2  |
| 26 | Schroeder V, Chatterjee T, Mehta H, Windecker S, Pham T, Devantay N, Meier B, <u>Kohler HP</u> . Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography.<br><i>Thromb Haemost</i> 88:1020-5, 2002.  | 8/61   | 4.9  |
| 27 | <u>Kohler HP</u> . Insulin resistance syndrome: interaction with coagulation and fibrinolysis.<br><i>Swiss Medical Weekly</i> 132:241-252, 2002.  | 37/102 | 1.5  |
| 28 | Ferrari P, Schroeder V, Anderson S, Kocovic L, Vogt B, Schiesser D, Marti HP, Ganz R, Frey F, <u>Kohler HP</u> . Plasminogen activator inhibitor-1 genotype and increased risk of avascular osteonecrosis in renal allograft recipients.<br><i>Transplantation</i> 74:1147-1152, 2002.  | 3/18   | 3.6  |

- 29 Schroeder V, Kucher N, Kohler HP. Role of thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with acute pulmonary embolism. *J Thromb Haemost* 1:492-493, 2003. 4.9
- 30 Kucher N, Kohler HP, Dornhoefer T, Wallmann D, Lämmle B. Accuracy of D-dimer/Fibrinogen Ratio to predict pulmonary embolism: a prospective diagnostic study. *J Thromb Haemost* 1:708-713, 2003. 4.9
- 31 Chatterjee T, Schroeder V, Windecker S, Meier B, Kohler HP. Venous and intracoronary factor XIII A-subunit antigen and activity levels are not associated with extent of coronary artery disease. *J Thromb Haemost* 1:861-863, 2003. 4.9
- 32 Kucher N, Schroeder V, Kohler HP. Role of blood coagulation factor XIII in patients with acute pulmonary embolism. Correlation of factor XIII antigen levels with pulmonary occlusion rate, fibrinogen, D-Dimer, and clot firmness. *Thromb Haemost* 90:434-38, 2003. 8/61 4.9
- 33 Schroeder V, Kohler HP. Factor XIII activation by thrombin depends on FXIIIVal34Leu genotype [letter]. *Blood* 101: 371-72, 2003. 2/61 10.1
- 34 Zeerleder A, Schroeder V, Hack C.E, Kohler HP, Wuillemin W. TAFI and PAI-1 levels in human sepsis. *Thromb Res* 2006 (*in press*) 29/61 1.8
- 35 Schroeder V, Meili E, Cung T, Schmutz P, Kohler HP. Characterisation of six novel A-subunit mutations leading to congenital factor XIII deficiency and molecular analysis of the worldwide first diagnosed patient with this rare bleeding disorder. *Thromb Haemost* 95:77-84, 2006 8/61 4.9